Save
The German MS Register: update on immunotherapy
Author(s): ,
A Stahmann
Affiliations:
MS Forschungs- und Projektentwicklungs-gGmbH, Hannover
,
K Buckow
Affiliations:
Medical Informatics, University Medical Center Göttingen
,
D Ellenberger
Affiliations:
Medical Statistics, University Medical Centre Göttingen, Göttingen
,
D Heymann
Affiliations:
German Multiple Sclerosis Society, Hannover
,
M Mai
Affiliations:
German Multiple Sclerosis Society, Hannover
,
T Meißner
Affiliations:
Medical Informatics, University Medical Center Göttingen
,
U Zettl
Affiliations:
Klinik und Poliklinik für Neurologie, Universitätsklinikum Rostock, Rostock, Germany
for the German Multiple Sclerosis Register of the German National MS Society (DMSG)
for the German Multiple Sclerosis Register of the German National MS Society (DMSG)
Affiliations:
ECTRIMS Online Library. Stahmann A. Sep 16, 2016; 145822
Alexander Stahmann
Alexander Stahmann
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1138

Type: Poster

Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression

Background: Disease-modifying drugs (DMD) serve to alter the long-term course of MS by reducing the inflammatory aspects of the disease. Currently, Immunotherapy is available for relapsing-remitting (RRMS) and secondary progressive (SPMS) forms of MS, none of the licensed drugs has proven efficacy in primary progressive MS (PPMS) and thus current S2e-guidelines in Germany do not foresee DMD treatment. Conversely, a recent study by Petersen et al. (2014) based on claims data by health insurance funds showed high numbers of PPMS-patients receiving DMD-treatment (1). Data from the German MS-Register were analysed in an attempt to verify these findings based on clinical data.

Methods: In 2014 the German MS-Register established new data set and register infrastructure. Currently 65 out of 165 participating centres in the register already use the new dataset and infrastructure, and further are currently migrating. This analysis is based on data sets collected from 2014 until 04/2016. A total of 3132 patients were enrolled in the new database. Data related to DMD-treatment and course of disease was available for 2744 of them. Proportion of patients receiving treatment are given for each disease course along with 95%-Clopper-Pearson confidence intervals. Global test for differences between courses are done with Chi²-test.

Results: The number of patients receiving DMD-treatment differed substantially between RRMS, SPMS and PPMS (p< 0.001): 85.1% of patients with RRMS (95%-CI: [83.4-86.6%]; n=1981) received DMD-treatment, while 53.2% of SPMS patients (95%-CI: [48.8-57.6%]; n=511) were treated with DMDs. 32.3% of the PPMS patients (95%-CI: [25.0-40.2%]; n=155) received DMD treatment.

Conclusions: The updated results show that a high proportion of MS patients receive DMD treatment which is in line with previous analyses and other investigations. The amount of PPMS patients receiving DMD treatment in conflict with the guidelines, is lower than in our older analyses from 2009 but is still high and confirms the findings of the population based analysis (1). The reduction in comparison to our analysis in 2009 [59% of PPMS patients received DMD treatment] could indicate a stronger adherence to the guidelines. This might be influenced by health insurance funds claiming damages if treatment is not in line with the guidelines.

Reference:

1. Petersen G, et al. Epidemiologie der Multiplen Sklerose in Deutschland. Nervenarzt. 2014;85(8)

Disclosure:

Buckow, Ellenberger, Mai, Meißner and Stahmann: nothing to disclose.

Heymann; Received a travel grant by Merck Serono.

Zettl: Received institutional research grants and personal honoraria as speaker from Biogen Idec, Bayer, Genzyme, Merck Serono, Novartis and TEVA Sanofi

The German MS Society, National Association yearly publishes the received grants and sources of funding: www.dmsg.de - The consented guidelines by the association of self-help organizations and the DMSG-guidelines for co-operation with (pharmaceutical) companies apply.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings